Global Zoonotic Disease Treatment Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Zoonotic Disease Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Zoonotic Disease Treatment Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 36.85 Billion
Diagram Market Size (Forecast Year)
USD 57.68 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Zoonotic Disease Treatment Market, By Types (Rabies, Tuberculosis, Malaria, Leishmaniasis, Ebola Virus Disease, Others), Causative Agent (Bacteria, Virus, Nematode, Rodents, Ticks, Others), Drug Class (Anti-fungal, Anti-bacterial, Antibiotics, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Zoonotic Disease Treatment Market

Market Analysis and Size

In recent years, the zoonotic disease treatment market is anticipated to grow rapidly during the forecast period. Depending on the infection, aetiology, and treatment, zoonotic disease can range from mild to deadly and even result in death. According to the World Health Organization (WHO), zoonotic diseases cause over one billion infections and millions of deaths each year, accounting for 60% of all new infectious diseases globally. A rise in zoonotic infections is also being attributed to a crowded environment, poor hygiene, climate and habitat changes, animal raising, and a lack of understanding. Diagnostics, treatment, and vaccine development are moving rapidly, further enhancing the demand for zoonotic disease treatment in the market.

Data Bridge Market Research analyses that the zoonotic disease treatment market was valued at USD 36.85 billion in 2021 and is expected to reach USD 57.68 billion by 2029, registering a CAGR of 5.76% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Zoonotic diseases are a type of unpredictable illness that is passed from animals to humans and from humans to animals. There are still various ways for disease to be transmitted, including airborne, direct interaction, connection with an inactive thing that docks the illness, oral absorption, and pest. Individuals may become ill or die due to the diseases spread by wiretaps and other wildlife. It is always important to remember that animals do not always appear sickly or sick when they are carrying a zoonotic disease. Several organisms appear to be healthy, but they spread infectious bacteria that can make people sick. Anti-fungal, anti-bacterial, and antibiotics are the various treatment options for this disease.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Types (Rabies, Tuberculosis, Malaria, Leishmaniasis, Ebola Virus Disease, Others), Causative Agent (Bacteria, Virus, Nematode, Rodents, Ticks, Others),  Drug Class (Anti-fungal, Anti-bacterial, Antibiotics, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Gilead Sciences, Inc. (US), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Zydus Cadila (India), Aurobindo Pharma (India), Cipla Inc. (US), Hikma Pharmaceuticals PLC (UK), Dr. Reddy’s Laboratories Ltd. (India), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Lannett (US), Torrent Pharmaceuticals Ltd. (India)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Zoonotic Disease Treatment Market Dynamics

Drivers

  • Increasing prevalence of zoonotic disease

The rising prevalence of zoonotic disease is anticipated to enhance the treatment demand and further propelling market's growth rate. The growing population, compromised hygiene, climate and habitat changes are the major factors influencing the market dynamics during the forecast period.   

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of zoonotic disease treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising focus on plastic surgeries will expand the zoonotic disease treatment market. Additionally, high disposable income and increasing urbanization will expand the zoonotic disease treatment market. Along with this, rising demand for disease-specific novel treatment and increasing use of antibiotics will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the zoonotic disease treatment market growth. Along with this, rising approvals and launches of new zoonotic disease treatment drugs will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the zoonotic disease treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, patent expiration of branded drugs and introduction of generics will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the zoonotic disease treatment market. Additionally, high capital investment required for research and development and the lack of awareness will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This zoonotic disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the zoonotic disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Zoonotic disease treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Zoonotic Disease Treatment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The zoonotic disease treatment market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the zoonotic disease treatment market's revenue trajectory.

Global Zoonotic Disease Treatment Market Scope

The zoonotic disease treatment market is segmented on the basis of types, causative agent, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Rabies
  • Tuberculosis
  • Malaria
  • Leishmaniasis
  • Ebola Virus Disease
  • Others

Based on types, the zoonotic disease treatment market is segmented into rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and others.

Causative Agent

  • Bacteria
  • Virus
  • Nematode
  • Rodents
  • Ticks
  • Others

Based on causative agent, the zoonotic disease treatment market is segmented into bacteria, virus, nematode, rodents, ticks, and others.

Drug Class

  • Anti-fungal
  • Anti-bacterial
  • Antibiotics
  • Others

Based on drug class, the zoonotic disease treatment market is segmented into anti-fungal, anti-bacterial, antibiotics, and others.

Route of Administration

  • Oral
  • Topical
  • Others

The route of administration segment for global zoonotic disease treatment market is segmented into oral, topical and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the zoonotic disease treatment market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the zoonotic disease treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Zoonotic Disease Treatment Market Regional Analysis/Insights

The Zoonotic disease treatment market is analysed and market size insights and trends are provided by country, types, causative agent, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Zoonotic disease treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the zoonotic disease treatment market due to rapid urbanization and the rising prevalence of zoonotic disease. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rising number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Zoonotic Disease Treatment Market Share Analysis

The Zoonotic disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to zoonotic disease treatment market.

Some of the major players operating in the zoonotic disease treatment market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France), Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Gilead Sciences, Inc. (US)
  • Apotex Inc. (Canada)
  • Amneal Pharmaceuticals LLC. (US)
  • Zydus Cadila (India)
  • Aurobindo Pharma (India)
  • Cipla Inc. (US)
  • Hikma Pharmaceuticals PLC (UK)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • WOCKHARDT (India)
  • Bausch Health Companies Inc. (Canada)
  • Lannett (US)
  • Torrent Pharmaceuticals Ltd. (India) 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Zoonotic Disease Treatment Market will be projected to grow at a CAGR of 5.76% during forecast by 2029.
The Zoonotic Disease Treatment Market will be projected at USD 57.68 billion during forecast by 2029.
The major players operating in the Zoonotic Disease Treatment Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Gilead Sciences, Inc. (US), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Zydus Cadila (India), Aurobindo Pharma (India), Cipla Inc. (US), Hikma Pharmaceuticals PLC (UK), Dr. Reddy’s Laboratories Ltd. (India), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Lannett (US), Torrent Pharmaceuticals Ltd. (India).
The major countries covered in the Zoonotic Disease Treatment Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.